Posted by Michael Wonder on 01 Sep 2022
Janssen's Stelara gets insurance benefits as first-line therapy for ulcerative colitis
1 September 2022 - Janssen Korea said its ulcerative colitis Stelara (ustekinumab) won health insurance benefits as the primary treatment for ulcerative colitis in adults in Korea as of Thursday.
The reimbursement for Stelara will be recognised for moderate to severe ulcerative colitis adult patients who do not respond to or tolerate common drugs such as corticosteroids, 6-mercaptopurine or azathioprine, or those who are banned from using those drugs.
